Last reviewed 2026-06-10 · How we verify

mild to moderate dementia of the Alzheimer's type — Treatment Landscape & Competitive Intelligence

mild to moderate dementia of the Alzheimer's type (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

Marketed treatment landscape

Approved drugs treating mild to moderate dementia of the Alzheimer's type, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

1. Alpha Cognition · 1 drug in mild to moderate dementia of the Alzheimer's type

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in mild to moderate dementia of the Alzheimer's type:

• mild to moderate dementia of the Alzheimer's type treatment updates — RSS
• mild to moderate dementia of the Alzheimer's type treatment updates — Atom
• mild to moderate dementia of the Alzheimer's type treatment updates — JSON

Cite this brief

Drug Landscape (2026). mild to moderate dementia of the Alzheimer's type — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/mild-to-moderate-dementia-of-the-alzheimer-s-type. Accessed 2026-06-10.

Related

• mild to moderate dementia of the Alzheimer's type full disease profile — treatment pathway, diagnostics, guidelines
• Browse all CI briefs
• Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing